Moreover, we found that AKT-SOX2 axis is a modulator of cancer stemness and chemoresistance and developed a combination strategy using an AKT inhibitor to decrease SOX2 protein level and enhance OS sensitivity to chemotherapeutic drugs. The gene discussed is AKT1; the disease is cancer.